Drug intelligence / Profile preview

HP-3001

Development stage: Preclinical
Lead developer: Changchun Huapu Biotechnology
Modality: Vaccines & Immunotherapeutics

Overview

**HP-3001** is an investigational CpG-adjuvanted influenza vaccine developed by Huapu Biotechnology. The vaccine uses a CpG-based immunostimulatory adjuvant intended to activate innate immune signaling and enhance antigen-specific adaptive immune responses to influenza vaccination. Huapu Biotechnology has reported that the program's clinical trial application was accepted by China's Center for Drug Evaluation.

Targets

TLR9 (Toll-like receptor 9)

Beyond the preview

Go deeper on HP-3001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HP-3001.

Explore the full profile